US 7867515
Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
granted A61KA61K31/56A61K9/0056
Quick answer
US patent 7867515 (Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof) held by Teva Womans's Health, Inc. expires Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Teva Womans's Health, Inc.
- Grant date
- Tue Jan 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/56, A61K9/0056, A61K9/2018, A61K9/2054